Infant Bacterial Therapeutics
48.50 SEK
+0.41 %
Less than 1K followers
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Infant Bacterial Therapeutics
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| growth-% | |||||||
| EBITDA | -46.4 | -71.1 | -43.8 | -65.0 | -133.8 | -144.5 | -68.2 |
| EBIT | -47.2 | -71.9 | -44.6 | -65.8 | -134.6 | -145.3 | -69.0 |
| Profit before taxes | -46.3 | -72.0 | -45.0 | -65.5 | -123.1 | -136.9 | -65.2 |
| Net income | -46.3 | -72.0 | -45.0 | -65.5 | -123.1 | -136.9 | -65.2 |
| EPS | -4.13 | -6.41 | -4.01 | -5.83 | -9.95 | -10.16 | -4.84 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | |||||||
| EBIT-% | |||||||
| ROE | -9.1 % | -16.4 % | -11.4 % | -19.7 % | -40.3 % | -80.4 % | -61.9 % |
| ROI | -8.9 % | -16.0 % | -11.0 % | -18.7 % | -35.0 % | -57.1 % | -40.3 % |